Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
The Bull Case For Gilead Sciences (GILD) Could Change Following European Approval of Twice-Yearly HIV Prevention Injection
27.08.2025 10:17
Gilead Sciences announced that the European Commission has granted marketing authorization for Yeytuo (lenacapavir), the first and only twice-yearly injectable HIV-1 pre-exposure prophylaxis, allowing its use for adults and adolescents at increased risk in the European Union, Norway, Iceland, and Liechtenstein. This approval not only marks a regulatory milestone but also underscores lenacapavir's unique positioning as an innovative, long-acting preventive solution endorsed by both the FDA...
Analyst Says Gilead (GILD) is a ‘Very High Quality’ Cheap Stock – Here’s Why
27.08.2025 06:56
We recently published Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings. Gilead Sciences Inc (NASDAQ:GILD) is one of the top trending stocks to watch ahead of Nvidia earnings. Rob Sechan from NewEdge Capital Group said in a recent program on CNBC that he’s buying Gilead Sciences Inc (NASDAQ:GILD) and explained his bullish case […]
Top 5 Dividend Stocks For Steady Income
22.08.2025 05:00
Indexes hit highs on Fed cut hopes, but inflation risks and FOMC tensions loom. Consider five dividend stocks for steady income amid uncertainty. See more here.
Gilead Sciences' Outperformance Means Overvalued
18.08.2025 04:16
Gilead Sciences' valuation exceeds fundamentals, prompting a SELL recommendation. Discover why this $150B biopharma stock may no longer justify its price.
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus
12.08.2025 07:29
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.
Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir
12.08.2025 00:19
Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc. (NASDAQ:GILD) has received a favorable opinion from the European Medicines Agency’s CHMP for lenacapavir (Yeytuo®), a twice-yearly injectable HIV PrEP alternative. It will be the first of its kind in the EU if it is […]
Gilead Surges 8%, Flirting With A Breakout, On Growing Enthusiasm For HIV PrEP
08.08.2025 14:32
Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV prevention.
Stock Market Today: Dow Rises, But Under Armour Plunges On This Warning (Live Coverage)
08.08.2025 13:45
Stock Market Today: The Dow Jones index rose Friday, but Under Armour plunged 22% on earnings. Trade Desk, Pinterest and Twilio also crumbled.
Trade Desk downgraded, Instacart upgraded: Wall Street's top analyst calls
08.08.2025 13:39
Trade Desk downgraded, Instacart upgraded: Wall Street's top analyst calls
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients
08.08.2025 05:13
Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why CGEN stock is a buy.
Stocks rise on Wall Street and hold on to weekly gains
08.08.2025 05:02
Gilead Sciences jumped 8.4% for one of the biggest gains on the market. The main focus throughout the week has been on President Donald Trump’s trade war and its potential impact on the U.S. economy, as well as the Federal Reserve’s interest rate policy. Trump began imposing higher import taxes on dozens of countries Thursday.
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
01.08.2025 13:28
BEIJING, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company,” “we,” “our” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today issued the following statements in response to recent market volatility and a third-party publication that has raised questions and concerns among shareholders. Over the past few days, shares of Pheton have experienced an extraordinary and unexpecte
BMO says WSJ report on RFK potential headwind for Gilead
29.07.2025 13:55
BMO Capital keeps an Outperform rating Gilead (GILD) after the Wall Street Journal reported that Robert F. Kennedy Jr. plans to remove all members of the preventative services task force. The views the report as a potential headwind to Gilead, saying the Supreme Court’s Braidwood decision only concretized the power of RFK’s Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting pre-exposure prophylaxis. BMO says that while there was
Gilead Sciences stock falls amid reports of preventive health panel dismissal
28.07.2025 13:54
Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members of a key advisory panel that influences insurance coverage requirements for preventive medications, including HIV drugs that Gilead produces. The Wall Street Journal reported Friday that Kennedy intends to remove all 16 members of the U.S. Preventive Services Task Force, viewing them as too "woke," according to
Gilead wins positive European approval opinion for twice-yearly HIV injection
28.07.2025 11:04
The CHMP positive recommendation comes a month after the WHO backed the drug for global HIV prevention.
HCSA Community Services and Tan Tock Seng Hospital Sign MOU to Hepatitis C Elimination in Singapore
28.07.2025 08:11
In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, today signed a Memorandum of Understanding (MoU) to reinforce their shared commitment to eliminating Hepatitis C (HCV) among former drug offenders in Singapore, the World Health Organization's global strategy of eliminating Hepatitis C.
Citi Maintains a Buy Rating on Gilead Sciences (GILD)
28.07.2025 06:08
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on July 21, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a price target of $125.00. On July 14, Gilead Sciences, Inc. (NASDAQ:GILD) presented new data on the twice-yearly […]
TD Cowen Remains Bullish on Gilead Sciences (GILD)
28.07.2025 06:07
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable biotech stocks to invest in now. TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) on July 23, setting a price target of $110.00. Buren based the optimistic rating on the company’s market position and financial projections, increasing the […]
CAR T-Cell Therapy Market Trends and Forecasts, 2021-2024 & 2025-2033 | Focus on Yescarta, Tecartus, Kymriah, Breyanzi, Abecma, Carvykti, and Carteyva
24.07.2025 08:20
The global CAR T-cell therapy market is set to expand from USD 4.6 billion in 2024 to USD 18.1 billion by 2033, driven by rising cancer cases and demand for personalized medicine. Key players like Novartis and Gilead Sciences lead in innovation. Market growth is fueled by ongoing clinical trials and investments.Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market Size, Growth, Share, Trends and Forecasts 2025-2033" report has been added to ResearchAndMarkets.com's offering. T
What to Expect From Gilead Sciences’ Q2 2025 Earnings Report
23.07.2025 05:58
Gilead Sciences is expected to announce its fiscal second-quarter earnings next month, and analysts forecast a single-digit drop in its earnings.